BioNTech’s (BNTX) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank restated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Friday,MarketScreener reports.

Several other brokerages have also recently commented on BNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. UBS Group raised shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $140.00 target price on shares of BioNTech in a report on Thursday, December 11th. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $140.03.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $115.98 on Friday. The company has a market capitalization of $26.12 billion, a PE ratio of -44.10 and a beta of 1.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. The stock has a fifty day moving average of $99.39 and a 200-day moving average of $103.62. BioNTech has a one year low of $81.20 and a one year high of $126.77.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The company had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the firm earned $0.81 earnings per share. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. As a group, equities analysts anticipate that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in BNTX. Dodge & Cox increased its holdings in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after buying an additional 2,769,654 shares during the last quarter. Bank of America Corp DE grew its position in BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after acquiring an additional 444,332 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of BioNTech by 58.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after purchasing an additional 410,351 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of BioNTech by 1,664.6% during the 4th quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock valued at $34,780,000 after purchasing an additional 344,630 shares in the last quarter. Finally, Aberdeen Group plc lifted its stake in shares of BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after purchasing an additional 336,260 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.